|By PR Newswire||
|August 14, 2014 02:11 PM EDT||
GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ -- Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.
In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been granted certain rights to deploy lentiviral technology in specified therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier. These rights include specified CAR T-cell based therapies as well as specified therapies for single-gene diseases and disorders.
Chimeric antigen receptor T cell therapy (CAR+ T) technologies have made significant advances during the past several years, as evidenced by consistent clinical results reported by several academic teams. "We are pleased that Lentigen Corporation has been at the forefront of the lentiviral vector manufacturing innovation that has enabled these advances in the treatment of hematologic malignancies," said David Wetherell, Chairman of Lentigen Corporation. He added, "this transaction will provide Opus Bio with ongoing access to innovations in lentiviral vector and cell processing technologies, while allowing the company to commit further resources toward the advancement its research and clinical development programs."
Opus Bio intends to make further announcements on the progress of its therapeutic pipeline during the coming months.
Opus Bio is a clinical-stage biotechnology company committed to developing potentially transformative cell therapies for cancer and single gene disorders. The company is backed by Biomark Capital, a life sciences and healthcare investment firm with offices in Greenwich, CT and San Francisco, CA.
Investor and media contact:
Douglas D. Lind, MD
Interim Chief Executive Officer
Opus Bio, Inc.
SOURCE Opus Bio, Inc.
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Dec. 2, 2016 03:15 PM EST Reads: 1,433
Dec. 2, 2016 02:15 PM EST Reads: 1,497
Dec. 2, 2016 02:02 PM EST Reads: 210
Dec. 2, 2016 02:00 PM EST Reads: 4,807
Dec. 2, 2016 01:30 PM EST Reads: 5,686
Dec. 2, 2016 01:30 PM EST Reads: 1,803
Dec. 2, 2016 01:15 PM EST Reads: 2,070
Dec. 2, 2016 01:00 PM EST Reads: 1,382
Dec. 2, 2016 01:00 PM EST Reads: 2,441
Dec. 2, 2016 12:11 PM EST Reads: 228
Dec. 2, 2016 12:00 PM EST Reads: 175
Dec. 2, 2016 12:00 PM EST Reads: 1,825
Dec. 2, 2016 11:45 AM EST Reads: 1,455
Dec. 2, 2016 11:30 AM EST Reads: 1,847
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
Dec. 2, 2016 11:30 AM EST Reads: 3,739